Niki BioSolutions, Inc.
No SEC Form 4 filings for $NIKI in the last 30 days.
See all $NIKI insider activity →Niki BioSolutions (NASDAQ:NIKI) subsidiary DiamiR Biosciences will genotype plasma samples from the Bio-Hermes-002 Alzheimer’s study, using its approved APOE genotyping assay. The data will be integrated into the study’s dataset, aiding clinical trial design and risk assessment. Niki BioSolutions operates a CLIA-certified lab for genomic and biomarker testing.
Niki BioSolutions (NIKI) appointed Thomas Freeburg as CFO, effective September 1, 2026. Freeburg, 59, previously held CFO/CAO roles at Interpace Biosciences and SEC reporting roles at Coach and Scholastic. The appointment is under a two-year agreement, according to an SEC filing.
Niki BioSolutions, Inc. (NIKI) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers . On October 9, 2026, the Board of Directors (the “Board”) of Niki BioSolutions, Inc., a Delaware corporation (the “Company”), appointed Thomas Freeburg as the Chief
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning NIKI (Niki BioSolutions, Inc.). Coverage has skewed bullish: 1 bullish, 2 neutral, and 0 bearish.
Recent NIKI coverage spans corporate actions, financial news and mergers & acquisitions.
The announcement adds a novel diagnostic capability, potentially enhancing the company's pipeline and attracting research collaborations.
The CFO appointment signals a leadership change but no immediate financial impact.
New CFO appointment may lead to modest market reaction as investors assess leadership change.
The ATM program introduces new shares, creating dilution risk and modest upward pressure on cash.
The ATM program introduces potential dilution and short‑term selling pressure.
AlphAI scores every news story that mentions NIKI with an AI model for sentiment and relevance, and aggregates insider trades from Niki BioSolutions, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Niki BioSolutions (NASDAQ:NIKI) subsidiary DiamiR Biosciences will genotype plasma samples from the Bio-Hermes-002 Alzheimer’s study, using its approved APOE genotyping assay. The data will be integrated into the study’s dataset, aiding clinical trial design and risk assessment. Niki BioSolutions operates a CLIA-certified lab for genomic and biomarker testing.
1 min readNiki BioSolutions (NIKI) appointed Thomas Freeburg as CFO, effective September 1, 2026. Freeburg, 59, previously held CFO/CAO roles at Interpace Biosciences and SEC reporting roles at Coach and Scholastic. The appointment is under a two-year agreement, according to an SEC filing.
1 min readNiki BioSolutions, Inc. (NIKI) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers . On October 9, 2026, the Board of Directors (the “Board”) of Niki BioSolutions, Inc., a Delaware corporation (the “Company”), appointed Thomas Freeburg as the Chief
1 min readNiki BioSolutions (NIKI) launched a $1.396M ATM equity program with H.C. Wainwright as sales agent. The company can sell common stock at market prices, with a 3.0% placement fee. The program allows flexible equity financing and can be terminated at any time.
1 min readNiki BioSolutions, Inc. (NIKI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry Into a Material Definitive Agreement. On October 9, 2026, Niki BioSolutions, Inc. (the “Company”), entered into an At the Market Offering Agreement, dated October 9, 2026, (the “ Sales Agreement ”), by and among the Company , H.C. Wainwright & Co., LLC (“ Wainwri
2 min readNiki BioSolutions, Inc. (NIKI) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. In connection with the previously announced merger transaction, Mr. Ian Huen and Alidad Mireskandari became the CEO and CO
1 min readNiki BioSolutions, Inc. filed a request with the SEC to withdraw its Form F-3 registration statement, initially submitted on January 16, 2026. The company is no longer a Foreign Private Issuer and has filed a Form S-3 for a previously described offering. No securities were sold under the withdrawn registration.
1 min readNiki BioSolutions, Inc. (APM) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-3.2 3 ea029826201ex3-2.htm FORM OF BYLAWS FOR NIKI BIOSOLUTIONS, INC Exhibit 3.2 BY-LAWS OF NIKI BIOSOLUTIONS, INC. (THE “CORPORATION”) ARTICLE I OFFICES The registered office of Niki Biosolutions, Inc. (the “Corporation”) shall be in the State of Delaware. The Corporation als
2 min readAndean Precious Metals Corp. (TSX: APM, OTCQX: ANPMF) reported Q2 2026 production of 25,387 gold equivalent ounces, up 4% year over year, and 52,730 GEOs for the first half, up 15%. San Bartolome drove growth; Golden Queen was below prior quarter. The company deferred silver and gold inventory sales and said it had $204.1M liquid assets at Q1 end. Financial results are due Aug. 11.
3 min readAptorum Group Limited (NASDAQ: APM) and DiamiR Biosciences announced three presentations at the 2026 Alzheimer’s Association International Conference (July 11-15, London and online) featuring DiamiR’s blood-based biomarker work, including APOE genotyping and microRNA markers. Aptorum and DiamiR also reported merger shareholder approval on June 9, 2026, with closing expected before fiscal 2027.
3 min read
